Table 1.
Antimyeloma RWCP treatments during index and subsequent LOT.
| Treatment, n (%)a | Index LOT (N = 248) | 1st Subsequent LOT (n = 152) | 2nd Subsequent LOT (n = 74) | 3rd Subsequent LOT (n = 42) | ≥4th Subsequent LOT (n = 17) |
|---|---|---|---|---|---|
| Glucocorticoids | 227 (91.5) | 107 (70.4) | 47 (63.5) | 23 (54.8) | 9 (52.9) |
| PI | 135 (54.4) | 53 (34.9) | 24 (32.4) | 9 (21.4) | 8 (47.1) |
| Carfilzomib | 63 (25.4) | 22 (14.5) | 11 (14.9) | 3 (7.1) | 3 (17.6) |
| Bortezomib | 50 (20.2) | 24 (15.8) | 10 (13.5) | 5 (11.9) | 6 (35.3) |
| Ixazomib | 22 (8.9) | 7 (4.6) | 3 (4.1) | 1 (2.4) | 1 (5.9) |
| IMiD | 121 (48.8) | 51 (33.6) | 17 (23) | 10 (23.8) | 7 (41.2) |
| Pomalidomide | 74 (29.8) | 30 (19.7) | 7 (9.5) | 6 (14.3) | 4 (23.5) |
| Lenalidomide | 36 (14.5) | 9 (5.9) | 5 (6.8) | 3 (7.1) | 5 (29.4) |
| Thalidomide | 11 (4.4) | 11 (7.2) | 5 (6.8) | 1 (2.4) | 1 (5.9) |
| Iberdomide | 0 (0) | 1 (0.7) | 0 (0) | 0 (0) | 0 (0) |
| Alkylating agents | 108 (43.5) | 68 (44.7) | 29 (39.2) | 13 (31) | 5 (29.4) |
| Cyclophosphamide | 80 (32.3) | 43 (28.3) | 17 (23) | 7 (16.7) | 4 (23.5) |
| Bendamustine | 16 (6.5) | 14 (9.2) | 6 (8.1) | 2 (4.8) | 0 (0) |
| Melphalan | 14 (5.6) | 13 (8.6) | 6 (8.1) | 4 (9.5) | 0 (0) |
| Carmustine | 1 (0.4) | 1 (0.7) | 1 (1.4) | 1 (2.4) | 0 (0) |
| Other | 1 (0.4) | 0 (0) | 0 (0) | 1 (2.4) | 0 (0) |
| Melflufen | 0 (0) | 0 (0) | 1 (1.4) | 0 (0) | 1 (5.9) |
| Anti-CD38 mAb | 24 (9.7) | 16 (10.5) | 5 (6.8) | 11 (26.2) | 7 (41.2) |
| Daratumumab | 23 (9.3) | 13 (8.6) | 4 (5.4) | 5 (11.9) | 6 (35.3) |
| Isatuximab | 1 (0.4) | 3 (2) | 1 (1.4) | 6 (14.3) | 2 (11.8) |
| BCMA-targeted therapies | 7 (2.8) | 24 (15.8) | 21 (28.4) | 10 (23.8) | 7 (41.2) |
| CAR-T | 0 (0) | 0 (0) | 2 (2.7) | 0 (0) | 1 (5.9) |
| Bispecific antibody | 0 (0) | 5 (3.3) | 2 (2.7) | 0 (0) | 4 (23.5) |
| Antibody-drug conjugate | 7 (2.8) | 19 (12.5) | 17 (23) | 10 (23.8) | 3 (17.6) |
| Anthracyclines | 21 (8.5) | 8 (5.3) | 7 (9.5) | 4 (9.5) | 2 (11.8) |
| Topoisomerase inhibitor | 17 (6.9) | 6 (3.9) | 3 (4.1) | 1 (2.4) | 0 (0) |
| Histone deacetylase inhibitor | 12 (4.8) | 6 (3.9) | 0 (0) | 0 (0) | 0 (0) |
| Anti-SLAMF7 mAb | 9 (3.6) | 7 (4.6) | 0 (0) | 1 (2.4) | 2 (11.8) |
| BCL-2 inhibitor | 6 (2.4) | 3 (2) | 2 (2.7) | 2 (4.8) | 1 (5.9) |
| Selective inhibitor of nuclear export | 2 (0.8) | 11 (7.2) | 3 (4.1) | 3 (7.1) | 4 (23.5) |
| Other | 19 (7.67) | 9 (5.9) | 7 (9.5) | 4 (9.5) | 4 (23.5) |
BCMA B-cell maturation antigen, Bcl B-cell lymphoma, CAR chimeric antigen receptor, IMiD immunomodulatory drug, LOT line of therapy, mAb monoclonal antibody, RWCP real-world clinical practice, PI proteasome inhibitor, SLAM signaling lymphocytic activation molecule.
aPatients can be counted in >1 drug group.